$IMMB Please Read Key Post(Edited Feb.8th) As you can

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker MoneyMaker #804

$IMMB Please Read Key Post([b]Edited Feb.8th[/b]) >> As you can see the market here is wide open for growth and by [b]2018 will consist of a $21 Billion Industry with a steady growth of 7% per annum. More IMPORTANTLY we are in an transition period where MANY current PATENTS will EXPIRE, leaving the door wide open for IMMB![/b]

Why is that important to IMMB, [b]there is simply room for Competitors and definite interest for MERGERS/ACQUISITIONS of smaller cap companies.[/b] Something in this economy that is happening everyday.

[b]Well here is my take as to WHY you should BUY IMMB....

[/b]

[b]IMMB currently carries 4 patents one of which is the coveted HIV/AIDS PATENT valued at over $5 Million[/b] >> http://imagehost.vendio.com/a/8709739/view/Patent.png

So we are in the market. Now we need a game plan, well Dr. Harry Zhabilov worked his ass off for many years using his amazing scientific skills to create key patents... [b]IMMB then realizes they can tap into a Billion Dollar Market with his Patents which for the record we have not one but 4 Patents.[/b] ...Mr.Zhabilov is an amazing Doctor....but he can't do it on his own so on [b]October of 2012 he makes an even more Brilliant move than his Patent Creation, HE SIGNS a contract with Mr. Bo Linton and appointed him to be part of the Board of Directors .

Well for the people who don't know BO LINTON he has a habit of taking the companies he is involved with to the BIG BOARDS NYSE/NASDAQ)...His last one being MAGNEGAS whom just recently rang the closing bell![/b]

[b]As of February/2013 IMMB made another BIG move, they appointed Mr. Valentin Dimitrov to the board of directors of the company. Mr. Dimitrov is a CEO of M.T. Rose Corporation also Mr. Dimitrov is one of the owners of the second largest chemical plant in Bulgaria, Europe. [/b]

So now we have a growing Board with TOP notch Members whom carry HUGE connections.

[b]Still with me, well on November 2012 a HUGE NEWS RELEASE Link Provided[/b] >> http://www.otcmarkets.com/stock/IMMB/news

[b]Immunotech Laboratories Inc. Announces Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients[/b]

[b]Followed by a much BIGGER News RELEASE JAN/2013 Link Provided[/b] >> http://www.otcmarkets.com/stock/IMMB/news

[b]Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines [/b]

[b]Which in turn led to THE BIGGEST ONE TO DATE FEB/2013 Link Provided[/b] >> http://ih.advfn.com/p.php?pid=nmona&article=56128728

[b]Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures [/b]

A Follow up to the newly appointed Dimitrov >> http://ih.advfn.com/p.php?pid=nmona&article=56190456

[b]Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan

[/b]

If you are still with me you are now adding everything up and saying to yourself HOLY SH*T, [b]We are OFFICIALLY INVOLVED in THAT COVETED BILLION DOLLAR MARKET....and you should be saying IMMB is the MOST UNDERVALUED MEDICAL SCIENCE COMPANY in the OTC soon to be NASDAQ and or NYSE... [/b]

[b]KEY STATEMENTS FORM LAST PR >>

[/b]Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a [b]valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology.[/b]"

[b]The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required[/b].

From the 2ND last PR and in the words of MR.BO LINTON (read BOLD)>>

Mr. Linton further commented the company recently [b]received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug"[/b]. [i][color=red]If confirmed the initial order would be in excess of several Million Dollars[/color][/i]. [b]This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company . In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone. [/b]

Now that you are seeing what I am seeing I will show you the KICKER >>

[b]CURRENT SHARE STRUCTURE

[/b]OUTSTANDING SHARES 60,500,000 give or take a handful

[b]FLOAT 1 MILLION YES, MILLION (give or take a handful)CONFIRMED Jan.31/2013 in video interview with MR. LINTON[/b] (link provided ) >> http://www.otcmarkets.com/stock/IMMB/news

AUTHORIZED 150,000,000 (MAY BE HIGHER)

Want More, I have more >>

[b]INSIDERS HOLDINGS 98% of O/S Here is the PROOF[/b] >>

Name of Shareholder Number of Shares

Harry Zhabilov 24,895,646 41.11

Ara Ghanime 24,895,646 41.11

Dow Jones Link 2,773,500 4.58

Allie Chang 600,000 1.0

Paul Felizian 600,000 1.0

Lord George Equities 5,400,000 9.0

Joseph Pittera 250,000 0.41

Harout Tovmasyan 151,000 0.25

Elie Sakayan 50,000 0.08

Hagop Parseghian 600,000 1.0

Others 339,896 0.46

So there you have it!

[b]PS since last Wednesday JAN.30TH in case you missed it we have seen 587,375 Shares TRADED or for the most part BOUGHT and we are up from .06 to .39 with MAJOR NEWS PENDING....with that said we have seen [b]MAJOR BIDS UNTOUCHED[/b] where investors could have taken HUGE PERCENTAGE GAINS and SIMPLY REFUSED to knowing where IMMB is heading SHORT TERM and or LONG TERM! [/b]

Good LUCK and REMEMBER only use this as a reference an never spend more than you are willing to lose.

Your Friend Cheeky!

[b]PSS there is more to IMMB than HIV/AIDS Please go to WEBSITE and absorb as much as you can, They are diversified to say the least...link provided above![/b]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Core Lab's Quarterly Grit: Navigating a Turbulent Market

Updated Category News Views 71

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

Continue Reading
Infoya Surges with 665% Growth, Wins Fast 50 Spot

Updated Category News Views 102

From Humble Beginnings to High Achiever Alright, let's touch base on Canada's tech landscape for a moment. Infoya's leap into Deloitte's 2026 Technology Fast 50 isn't just a pat on the back—it's a flashing neon sign of what raw ambition mixed with a pinch of AI can cook up for you. They've banked a whopping 665% revenue growth from 2022 to 2025. Not bad for a company...

Continue Reading
White House Photographer Reveals Unseen Historic Moments

Updated Category News Views 94

You don’t just wander into the White House and leave unimpressed, not if you're someone who lived it like David Hume Kennerly. Imagine stepping behind those gates and through history's lens, capturing moments few had the privilege to see. Kennerly's debut as the Chief White House Photographer was at a turning point in America, just after the Nixon saga collapsed in...

Continue Reading
Doximity Faces Legal Heat: 23% Stock Plunge Analyzed

Updated Category News Views 12

Doximity's Rollercoaster: Steep Drop Amid Lawsuits Imagine watching your portfolio take a gut-wrenching plunge—and that's the rollercoaster ride Doximity investors experienced. On May 14, 2026, Doximity's stock nosedived by 23%, closing at $18.01 per share. This tumble, which marked a painful conclusion to a series of financial disappointments, has thrown the company...

Continue Reading
Xyte's Record Quarter: Surging Demand & New CEO

Updated Category News Views 0

Setting New Records in the AV Industry There's buzz in the air over in Hoboken, New Jersey. Xyte, the AI cloud maestro you're starting to hear about more and more, has just smashed its own records this past September. It's not just a flash in the pan, either—this isn't the first time they've knocked it out of the park. Thanks to burgeoning enterprise demand and a...

Continue Reading
Royce Micro-Cap Trust: Navigating Small-Cap Waves

Updated Category News Views 42

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Continue Reading
McKinsey and Parloa Join Forces on AI Customer Service

Updated Category News Views 66

AI-Revolutionizing Customer Service: The New Partnership Out of the boardroom and into the trenches, McKinsey joins hands with Parloa, aiming to reshape how enterprises handle customer service through artificial intelligence. Forget all the corporate fluff you've heard before; these guys are dead set on closing the massive gap companies face in deploying AI agents...

Continue Reading
BlueNord Signals Strategic Shift with Vår Energi Merger

Updated Category News Views 47

BlueNord's Bold Move in the Energy Sector With the ink barely dry on their third-quarter results, BlueNord has dropped a bombshell: a merger approved with Vår Energi. This isn't just another page in their corporate books—it's a strategic pivot that could redefine their place within the oil and gas arena. Anybody keeping an eye on the energy sector right now should sit...

Continue Reading
BetaNXT and Pave Finance Transform Wealth Management

Updated Category News Views 52

AI Takes Center Stage in Wealth Management You know, it's not every day we see two powerhouses like BetaNXT and Pave Finance buddying up to shake up the financial advisory world. This partnership's all about harnessing AI to give wealth management firms and financial advisors some serious firepower in portfolio planning. BetaNXT, already a big name with its slick...

Continue Reading
Storyteq's AI Edge Earns Gartner Leader Status Again

Updated Category News Views 69

Pioneering AI in Digital Asset Management Alright, folks, this ain't just another tech release to gloss over with your morning coffee—ITG's Storyteq has snagged the 'Leader' title in Gartner's Magic Quadrant for Digital Asset Management. It's no small feat to earn such recognition three years running, and the secret sauce is their advanced AI capabilities. A Unified AI...

Continue Reading

Top 5 Most Recently Viewed Articles

Rgenta Therapeutics Presents Innovative Data on RGT-61159

Updated Category News Views 192

Rgenta Therapeutics Unveils Preclinical Data on RGT-61159 WOBURN, Mass. – Rgenta Therapeutics, a pioneering biotechnology firm focused on the development of small molecule drugs targeting RNA for cancer and neurological disorders, has made an exciting announcement regarding its lead program, RGT-61159. This promising small molecule inhibitor, which selectively targets...

Continue Reading
TriMas Packaging Showcases Innovations at Upcoming Trade Events

Updated Category News Views 122

TriMas Packaging's Participation in Major Trade Shows TriMas Packaging, a leading group under TriMas (NASDAQ: TRS), is thrilled to announce its involvement in two prominent trade exhibitions. At these events, the company will display its extensive range of innovative and eco-friendly dispensing and closure product solutions that have garnered attention in the industry....

Continue Reading
Understanding Apollo Global Management's Recent Market Trends

Updated Category News Views 109

Understanding Apollo Global Management's Recent Market Trends The market is currently witnessing a notable shift in investor sentiment towards Apollo Global Management (NYSE: APO). This trend is not only striking but worth examining closely for anyone interested in market movements. Recent tracking of options activity has highlighted an interesting wave of bullish...

Continue Reading
Capricor Faces Securities Fraud Lawsuit: Investor Action Key

Updated Category News Views 16

Investors Take the Stage in Capricor Securities Case Here's something that'll make any shareholder's pulse quicken: Capricor Therapeutics, Inc. (NASDAQ: CAPR) is caught in a whirlwind of legal drama, and it's no soap opera. Rather, it's a class action lawsuit, brought forth by the vigilant folks over at Schall, Brown & Schwartz LLP ('SBS'), aimed squarely at alleged...

Continue Reading
Broad Arrow Auctions Collects $14.5 Million in Sales Triumph

Updated Category News Views 333

Broad Arrow Auctions Kicks Off a Successful Year Broad Arrow Auctions, an esteemed arm of Hagerty, recently embarked on its 2025 auction calendar with a remarkable showcase—the Academy of Art University Collection Auction. Held at the university's museum facilities, this auction captured the attention of classic car enthusiasts and collectors alike. A Glance at the...

Continue Reading